MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal

MapLight's schizophrenia drug fails once-daily test, shares plunge

MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents

MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst

MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut